Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback